MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
13 mai 2024 07h30 HE | MacroGenics, Inc.
ROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data
09 mai 2024 16h01 HE | MacroGenics, Inc.
Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09,...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
03 mai 2024 07h30 HE | MacroGenics, Inc.
ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
03 avr. 2024 16h30 HE | MacroGenics, Inc.
Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstractCompany plans to provide updated interim data,...
MacroGenics-Logo-(transparent-background).png
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
07 mars 2024 16h01 HE | MacroGenics, Inc.
Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
01 mars 2024 17h48 HE | MacroGenics, Inc.
ROCKVILLE, MD, March 01, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
27 févr. 2024 17h45 HE | MacroGenics, Inc.
ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conference
02 févr. 2024 16h30 HE | MacroGenics, Inc.
ROCKVILLE, MD, Feb. 02, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conference
08 janv. 2024 16h30 HE | MacroGenics, Inc.
ROCKVILLE, MD, Jan. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results
06 nov. 2023 16h01 HE | MacroGenics, Inc.
Completed enrollment of TAMARACK Phase 2 study of vobra duo ahead of scheduleInitiated LORIKEET Phase 2 study of lorigerlimab Submitted IND for MGC026, a topoisomerase inhibitor-based ADC Conference...